Literature DB >> 11059806

Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases.

A Greco1, L Minghetti, G Levi.   

Abstract

Isoprostanes are prostaglandin-like compounds which are formed by free radical catalysed peroxidation of arachidonic acid esterified in membrane phospholipids. They are emerging as a new class of sensitive, specific and reliable markers of in vivo lipid peroxidation and oxidative damage. Since their initial description of in 1990, the rapid development of analytical methods for isoprostane measurement has allowed to overcome some of the pitfalls of the previous and most widely used methods of assessing free radical injury. Here, we summarise the current knowledge on these novel class lipid peroxidation products and the advantages of monitoring their formation to better define the involvement of oxidative stress in neurological diseases. Although the literature data are still not abundant, they indicate that in vivo or post mortem cerebrospinal fluid and brain tissue levels of isoprostane are increased in some diseases such as multiple sclerosis, Alzheimer's disease, Huntington's disease, and Creutzfeldt-Jakob disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11059806     DOI: 10.1023/a:1007608615682

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  27 in total

Review 1.  Huntington's disease.

Authors:  S Davies; D B Ramsden
Journal:  Mol Pathol       Date:  2001-12

2.  Rapid quantitative analysis of 8-iso-prostaglandin-F(2alpha) using liquid chromatography-tandem mass spectrometry and comparison with an enzyme immunoassay method.

Authors:  Jeffrey H Dahl; Richard B van Breemen
Journal:  Anal Biochem       Date:  2010-05-25       Impact factor: 3.365

Review 3.  Biomarkers of Alzheimer disease in plasma.

Authors:  Michael C Irizarry
Journal:  NeuroRx       Date:  2004-04

Review 4.  Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood.

Authors:  Anders Lönneborg
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

5.  The effect of caloric restriction and glycemic load on measures of oxidative stress and antioxidants in humans: results from the CALERIE Trial of Human Caloric Restriction.

Authors:  M Meydani; S Das; M Band; S Epstein; S Roberts
Journal:  J Nutr Health Aging       Date:  2011-06       Impact factor: 4.075

Review 6.  Mitochondrial matters of the brain: the role in Huntington's disease.

Authors:  C Turner; A H V Schapira
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

Review 7.  Multiple actions of the human immunodeficiency virus type-1 Tat protein on microglial cell functions.

Authors:  Luisa Minghetti; Sergio Visentin; Mario Patrizio; Laura Franchini; Maria Antonietta Ajmone-Cat; Giulio Levi
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

8.  Influence of intensive multifunctional neurorehabilitation on neuronal oxidative damage in patients with Huntington's disease.

Authors:  Irene Ciancarelli; Daniela De Amicis; Caterina Di Massimo; Giorgio Sandrini; Caterina Pistarini; Antonio Carolei; Maria Giuliana Tozzi Ciancarelli
Journal:  Funct Neurol       Date:  2015 Jan-Mar

9.  Increased isolevuglandin-modified proteins in glaucomatous astrocytes.

Authors:  Bharathi Govindarajan; Anna Junk; Mabel Algeciras; Robert G Salomon; Sanjoy K Bhattacharya
Journal:  Mol Vis       Date:  2009-06-01       Impact factor: 2.367

Review 10.  Effects of antioxidant supplementation on the aging process.

Authors:  Domenico Fusco; Giuseppe Colloca; Maria Rita Lo Monaco; Matteo Cesari
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.